Acumen Pharmaceuticals (ABOS) director receives new RSU and option awards

Rhea-AI Filing Summary

Acumen Pharmaceuticals director John A. Stalfort III received new equity awards. On June 3, 2026, he was granted 35,500 restricted stock units, each representing one share of common stock, and 53,250 stock options with an exercise price of $2.29 per share.

The RSUs and the option grant will vest in full on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting, as long as he continues to serve through that date. Following these awards, he directly holds 220,624 shares of common stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Stalfort John A III

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	53,250	$0.00	--
Grant/Award	Common Stock	35,500	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 53,250 shares (Direct, null); Common Stock — 220,624 shares (Direct, null)

Footnotes (1)

1. Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

RSU grant: 35,500 RSUs Option grant size: 53,250 options Option exercise price: $2.29 per share +2 more

5 metrics

RSU grant 35,500 RSUs Awarded June 3, 2026 to director

Option grant size 53,250 options Stock Option (right to buy) granted June 3, 2026

Option exercise price $2.29 per share Conversion/exercise price for 53,250 options

Common shares after grant 220,624 shares Total common stock directly held following RSU award

Option expiration June 3, 2036 Expiration date of 53,250 stock options

Key Terms

restricted stock unit ("RSU"), contingent right, Stock Option (right to buy), vest in full, +1 more

5 terms

restricted stock unit ("RSU") financial

"Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right..."

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

Stock Option (right to buy) financial

"Stock Option (right to buy)"

vest in full financial

"The RSUs will vest in full on the earlier of the first anniversary of the date of grant..."

annual stockholder meeting financial

"...on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting..."

An annual stockholder meeting is a yearly gathering where a company's owners (shareholders) receive updates on performance, vote on key issues like board members, executive pay and major corporate plans, and ask questions of management. Think of it as a company town hall where choices about oversight and direction are decided; outcomes can affect management accountability, corporate strategy and ultimately the value and risks of investors’ shares.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stalfort John A III

(Last) (First) (Middle)

C/O ACUMEN PHARMACEUTICALS, INC.

1210-1220 WASHINGTON STREET, SUITE 210

(Street)

NEWTON MASSACHUSETTS 02465

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acumen Pharmaceuticals, Inc. [ ABOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/03/2026		A		35,500(1)	A	$0	220,624	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.29	06/03/2026		A		53,250		(2)	06/03/2036	Common Stock	53,250	$0	53,250	D

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

2. The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

Remarks:

	/s/ Derek Meisner, Attorney-in-Fact	06/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Acumen Pharmaceuticals (ABOS) director John A. Stalfort III receive in this Form 4?

He received equity compensation grants, not open-market trades. The filing shows 35,500 restricted stock units and 53,250 stock options, both awarded on June 3, 2026, as part of his service on Acumen Pharmaceuticals’ board of directors.

How many restricted stock units were granted to the Acumen Pharmaceuticals (ABOS) director?

He was granted 35,500 restricted stock units. Each RSU represents a contingent right to receive one share of Acumen Pharmaceuticals common stock, subject to vesting conditions tied to continued service and the timing of the 2027 annual stockholder meeting.

What are the terms of the stock options granted to the Acumen Pharmaceuticals (ABOS) director?

He received 53,250 stock options with an exercise price of $2.29 per share. These options vest in full on the earlier of the first anniversary of June 3, 2026, or the 2027 annual stockholder meeting, provided he continues serving until vesting.

When do the new RSU and option awards for Acumen Pharmaceuticals (ABOS) vest?

Both the RSUs and options vest in a single cliff. Vesting occurs on the earlier of the first anniversary of the June 3, 2026 grant date or the 2027 annual stockholder meeting, assuming the director’s continuous service through that date.

How many Acumen Pharmaceuticals (ABOS) shares does the director hold after these grants?

After the RSU grant, the filing reports he directly holds 220,624 shares of Acumen Pharmaceuticals common stock. This figure reflects his post-transaction share position, separate from the 53,250 options that give him the right to buy additional shares.

Do these Acumen Pharmaceuticals (ABOS) Form 4 transactions involve any stock sales?

No, the Form 4 only reports acquisitions through equity awards. The transactions are coded as grants or awards of RSUs and stock options, with no open-market purchases or sales and no dispositions for tax withholding or gifting reported in this filing.